Medpace price to free cash flow MEDP

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Oct 23, 2026: 26.4×
9-year median: 20.2×
Against its 9-year history: 89th; percentile: 0 is its lowest day, 100 its highest
9-year range: 12.0× to 33.3×
Peer median: 33.5×

Medpace's price to free cash flow is 26.4× as of Oct 23, 2026.

That is above its 9-year median of 20.2×, higher than on 89% of days in the last 9 years.

Over that time it ranged from 12.0× in May 2018 to 33.3× in Feb 2021.

The median for 10 diagnostics and research stocks of a similar size is 33.5×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.4×	16.5×	26.4×
2025	23.6×	15.3×	25.8×
2024	19.8×	18.0×	31.7×
2023	24.9×	15.5×	25.7×
2022	23.1×	18.0×	25.2×
2021	28.9×	24.6×	33.3×
2020	27.5×	13.1×	27.7×
2019	17.9×	12.7×	19.3×
2018	14.2×	12.0×	18.9×
2017	16.2×	14.0×	16.6×

Against its peers

Companies in Medical - Diagnostics & Research nearest Medpace's size, closest first, today.

Company	Price to free cash flow
MEDPMedpace	26.4×
RVTYRevvity	31.7×
LHLabcorp	23.1×
DGXQuest Diagnostics	19.8×
MTDMettler-Toledo International	38.7×
BIOBio-Rad Laboratories	28.0×
CAICaris Life Sciences	73.0×
ILMNIllumina	43.7×
IDXXIDEXX Laboratories	35.2×
WATWaters	112×
IQVIQVIA	21.1×
Peer median	33.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Medpace

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.